

August 03, 2023

The Manager
BSE Limited (SME),
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

Dear Sir,

Scrip No. 543363
BSE Symbol: PREVEST

Sub: Outcome of the Board Meeting held today i.e., August 03, 2023

With reference to the captioned subject and in compliance with the regulation 30 and 33 and other applicable regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., Thursday, August 03, 2023 (commenced at 01:00 a.m. and concluded at 02.45 p.m.), inter-alia has the following:

1. Considered and approved the un-audited (Standalone and consolidated) financial results of the Company for the quarter ended on June 30, 2023.
2. Considered and approved the Limited Review Report of the Auditors, in respect of the un-audited (Standalone and consolidated) financial results of the Company for the quarter ended on June 30, 2023.
3. Considered and approved the Directors' Report along with Management Discussion and Analysis Report for the financial year ended March 31, 2023.
4. Considered and decided to hold the 24th Annual General Meeting of the Members of the Company on Wednesday, August 30, 2023.
5. Considered and appointed **VNB and Company**, Chartered Accountants as an internal Auditor of the Company for the financial year 2023-24.
6. Considered and appointed **NKM and Associates**, Company Secretaries as a Secretarial Auditor of the Company for the financial year 2023-2024.
7. Recommendation of payment of Final Dividend on Equity Shares at the rate of 10% (Ten per cent) [i.e., 1.00/- (Rupees One Only) per Equity Share of Face Value of 10/- (Rupees Ten Only)] for the Financial Year ended March 31, 2023., subject to approval of shareholders at the ensuing Annual General Meeting. The dividend, if approved, shall be paid within the prescribed timeline. Promoters have volunteered to waive dividend on their holdings on equity shares for the Financial Year 2022-23

A copy of the un-audited (Standalone and consolidated) Financial Results adopted and approved by the Board of Directors for the quarter ended on June 30, 2023 and limited review report of the Auditors thereon is attached herewith for your perusal. Please take the same on your records and suitably disseminated at all concerned.

Thanking You,
Yours faithfully,

For Prevest Denpro Limited

Krishna Rathi
Company Secretary and Compliance officer
Membership No- 64330

Statement of unaudited Standalone Financials Results for the Quarter ended on 30th June 2023

		Quarter Ended			Year Ended
		30/06/2023	31/03/2023	30/06/2022	31/03/2023
PARTICULARS		Unaudited	Audited	Unaudited	Audited
1	Income From Operation				
	(a) Net Sales / Income from Operation (Net of Taxes)	1,339.40	1,377.35	1,236.61	4,985.41
	(b) Other Income	60.52	33.33	61.78	203.35
	Total Revenue	1,399.92	1,410.68	1,298.38	5,188.76
2	Expenses				
	(a) Cost of Material Consumed	352.84	299.27	370.03	1,276.08
	(b) Purchase of Stock-in- Trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(9.21)	2.60	(4.34)	(15.29)
	(d) Finance Cost	-	-	-	-
	(d) Employee benefit expenses	239.60	229.46	187.55	819.07
	(e) Depreciation and amortization expenses	17.49	15.68	14.64	67.51
	(f) Other Expenses	259.57	285.53	225.71	945.71
	Total Expenses	860.30	832.54	793.58	3,093.09
3	Profit/(Loss) from before exceptional and extraordinary items (1-2)	539.62	578.14	504.80	2,095.68
	Profit/(Loss) from ordinary activities, before finance cost and exceptional items (3+4)	539.62	578.14	504.80	2,095.68
	Financial Cost	-	-	-	-
	Profit/(Loss) from ordinary activities, after finance cost but before exceptional items (5-6)	539.62	578.14	504.80	2,095.68
4	Exceptional Item	-	-	-	-
5	Profit/(Loss) from ordinary activities before tax (3+4)	539.62	578.14	504.80	2,095.68
6	Tax Expenses				
	Current Tax	135.39	66.58	145.64	516.16
	Earliyer Year Tax	-	-	-	0.27
	Deffered Tax	-4.22	0.79	-9.02	8.24
7	Net Profit/(Loss) from Ordinary activity after tax (5-6)	408.45	510.77	368.18	1,571.01
8	Extraordinary Item (net of tax Rs expenses)	-	-	-	-
9	Net profit/(loss) for the period (7+8)	408.45	510.77	368.18	1,571.01
	Details of Share Capital				
10	Paid up Equity Share Capital-Face Value Rs 10/- each	120.00	120.00	120.00	120.00
11	Reserve excluding, Revaluation Reserves as per balance sheet of previous accounting year.	-	-	-	6,079.44
12	Earnings per Share (EPS) , in Rs (not annualised) (Equity Share of face value of Rs 10/- each)				
	(a) Basic	3.40	4.26	3.07	13.09
	(b) Diluted	3.40	4.26	3.07	13.09

Notes:-

- The above financial results were reviewed and recommended by the Audit Committee of the company and, the same were approved by the Board of Director of the company at their respective meeting/s held on Thursday, 3rd August 2023.
- The Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- The above Financial Statements have been prepared in accordance with applicable Accounting Standards issued by the Institute of Chartered Accountants of India
- The figures for the previous period have been restated / regrouped / reclassified, wherever necessary, in order to make them comparable.
- The figures of the quarter ended March 31, 2023 are the balancing figures between audited figures in respect of the full financial years and the unaudited published year-to-date figures upto December 31 which were subjected to limited review.


Atul Modi
 (Managing Director)
 DIN-00788272



Limited Review Report on Standalone Unaudited Quarter Ended financial results of PREVEST DENPRO LIMITED pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To,
The Board of Directors
Prevest Denpro Limited,

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Prevest Denpro Limited** ("the Company"), for the Quarter ended 30th June, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal & Associates
Chartered Accountants
FRN: 106456W

Hemant Bohra
Partner

M. NO.: 165667
UDIN: 23165667BGTIGR5736



Date: 03rd August, 2023
Place: Mumbai

Statement of Consolidated unaudited Financials Results for the Quarter ended on 30th June 2023

	PARTICULARS	Rs in Lakh
		Quarter Ended
		30/06/2023
		Unaudited
1	Income From Operation	
	(a) Net Sales / Income from Operation (Net of Taxes)	1,339.40
	(b) Other Income	60.52
	Total Revenue	1,399.92
2	Expenses	
	(a) Cost of Material Consumed	352.84
	(b) Purchase of Stock-in- Trade	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in- trade	(9.21)
	(d) Finance Cost	-
	(d) Employee benefit expenses	239.60
	(e) Depreciation and amortization expenses	17.49
	(f) Other Expenses	259.57
	Total Expenses	860.30
3	Profit/(Loss) from before exceptional and extraordinary items (1-2)	539.62
	Profit/(Loss) from ordinary activities, before finance cost and exceptional items (3+4)	539.62
	Financial Cost	
	Profit/(Loss) from ordinary activities, after finance cost but before exceptional items (5-6)	539.62
4	Exceptional Item	
5	Profit/(Loss) from ordinary activities before tax (3+4)	539.62
6	Tax Expenses	
	Current Tax	135.39
	Deferred Tax	-4.22
7	Net Profit/(Loss) from Ordinary activity after tax (5-6)	408.45
8	Extraordinary Item (net of tax Rs expenses)	
9	Net profit/(loss) for the period (7+8)	408.45
	Details of Share Capital	
10	Paid up Equity Share Capital-Face Value Rs 10/- each	120.00
11	Reserve excluding, Revaluation Reserves as per balance sheet of previous accounting year.	
12	Earnings per Share (EPS) , in Rs (not annualised) (Equity Share of face value of Rs 10/- each)	
	(a) Basic	3.40
	(b) Diluted	3.40

Notes:-

- The above Consolidated financial results were reviewed and recommended by the Audit Committee of the company and, the same were approved by the Board of Director of the company at their respective meeting/s held on Thursday, 3rd August 2023.
- This consolidated financial result includes, results of Denvisio Biomed Limited (Wholly Owned Subsidiary of Prevest Denpro Limited)
- As the company has prepared consolidation financial results for the first time comparative figures is not provided.
- The Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- The above Consolidated Financial Statements have been prepared in accordance with applicable Accounting Standards issued by the Institute of Chartered Accountants of India



Atul Modi
(Managing Director)
DIN-00788272



Independent Auditor's Limited Review Report on Consolidated Unaudited Quarter Ended financial results of PREVEST DENPRO LIMITED pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To,
The Board of Directors
Prevest Denpro Limited,

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Prevest Denpro Limited** ("the Company"), for the Quarter ended 30th June, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Consolidated unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

This statement Includes the results of the following entities: -

- I. Denvisio Biomed Limited (Wholly Owned Subsidiary)

For Mittal & Associates
Chartered Accountants

FRN: 106456W

Hemant Bohra
Partner

M. NO.: 165667

UDIN: 23165667BGTIGS7624



Date: 03rd August, 2023

Place: Mumbai